- Distribution agreement to take effect as of 2021
- New agreement applies to Bormed™ portfolio of innovative polyolefin grades for healthcare
- Complementary Borealis and IMCD product portfolios to enable even more choice in polymers
Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European distributor of its dedicated grade range of Bormed™ polyolefins for healthcare. The distribution agreement covers most of Europe (with the exception of Switzerland and the South-Eastern countries1) and takes effect as of 2021. It applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices.
As a distributor with strong presence in medical and healthcare applications, IMCD is the ideal partner for Borealis customers in Europe thanks to its broad technical expertise and dedicated medical application team. The extensive IMCD polymers range complements the Borealis Bormed portfolio, opening a range of new possibilities. IMCD was selected from a broad field of potential distributors following a rigorous screening process.
“We are pleased to have found in IMCD a partner sharing the core Bormed values of service, commitment and conformance,” said John Webster, Borealis Head of Sales Advanced Products. “What also unites us is our dedication to providing best-in-class service to all of our healthcare customers, both direct and indirect, by way of more intensive and efficient value chain collaboration. We are confident that this new agreement will significantly boost our presence in this increasingly important sector.”
In line with its commitment to service as the foundation of successful industry co-operation, Borealis and IMCD will together ensure a seamless distribution transition for their customers, who can continue to count on security of supply as well as the ready assistance of experienced technical and sales teams.
Olivier Champault, Director of IMCD Business Group Advanced Materials: “We are delighted to be selected as the new partner for Borealis in their healthcare business. This partnership is completely aligned with our strategy to further expand and strengthen our presence in the medical and healthcare segment in Europe. With our dedicated experts in medical and healthcare applications, our well-establish distribution network, and our board product offering, we are fully committed to accelerate growth and to support our customers in their developments and innovations.”
1 The distribution agreement covers most of Europe, with the exception of Switzerland, Albania, Bulgaria, Romania, Macedonia, Slovenia, Hungary, Bosnia-Herzegovina, Croatia, Kosovo, Montenegro and Serbia.
About Borealis:
Borealis is one of the world’s leading providers of advanced and circular polyolefin solutions and a European market leader in base chemicals, fertilizers and the mechanical recycling of plastics. We leverage our polymers expertise and decades of experience to offer value adding, innovative and circular material solutions for key industries. In re-inventing for more sustainable living, we build on our commitment to safety, our people and excellence as we accelerate the transformation to a circular economy and expand our geographical footprint.
With head offices in Vienna, Austria, Borealis employs 6,900 employees and operates in over 120 countries. In 2020, Borealis generated EUR 6.8 billion in sales revenue and a net profit of EUR 589 million. OMV, the Austria-based international oil and gas company, owns 75% of Borealis, while the remaining 25% is owned by a holding company of the Abu-Dhabi based Mubadala. We supply services and products to customers around the globe through Borealis and two important joint ventures: Borouge (with the Abu Dhabi National Oil Company, or ADNOC, based in UAE); and Baystar™ (with Total, based in the US).
About Borealis Healthcare: Because we care
As a leading supplier of innovative products and solutions for the healthcare industry, Borealis has been delivering value creation through innovation to its customers for over 30 years. Building on its portfolio of dedicated Bormed™ products and the three principles of the Bormed Concept – Commitment, Service and Conformance – Borealis offers advanced polyolefins for medical devices, pharmaceuticals and diagnostic packaging. Its solutions provide superior technical performance and fulfil the most specific and stringent requirements when it comes to safety and quality. Its long-term commitment to working with its customers to address tomorrow’s healthcare challenges makes it a reliable and trusted partner. As a global supplier, Borealis can ensure the security of supply and provide tailored technical support.
About IMCD Group:
The IMCD Group is a global market-leader in the sales, marketing, and distribution of speciality chemicals and ingredients. Its result-driven professionals provide market-focused solutions to suppliers and customers across EMEA, Americas and Asia-Pacific, offering comprehensive product portfolios ranging from home, industrial and institutional care, personal care, food and nutrition and pharmaceuticals to lubricants and energy, coatings and construction, advanced materials, and synthesis.
The IMCD Group realised revenues of EUR 2,775 million in 2020 with nearly 3,300 employees in over 50 countries. IMCD’s dedicated team of technical and commercial experts work in close partnership to tailor best-in-class solutions and provide value through expertise for around 50,000 customers and a diverse range of world class suppliers. IMCD shares are traded at Euronext, Amsterdam (IMCD).
Further information:
www.borealisgroup.com
www.borealisgroup.com/polyolefins/healthcare
www.borealiseverminds.com
www.imcdgroup.com